
Robert Howard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10574708/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Suicidal ideation in dementia: associations with neuropsychiatric symptoms and subtype diagnosis. International Psychogeriatrics, 2022, 34, 399-406.	1.0	2
2	Psychiatric disorders and risk of subsequent dementia: Systematic review and metaâ€analysis of longitudinal studies. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	29
3	Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer's disease: systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1080-1090.	1.9	24
4	Adapting and Optimizing Problem Adaptation Therapy (PATH) for People With Mild-Moderate Dementia and Depression. American Journal of Geriatric Psychiatry, 2021, 29, 192-203.	1.2	5
5	Pharmacological treatment trials of agitation in Alzheimer's disease: A systematic review of ClinicalTrials.gov registered trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12157.	3.7	6
6	Non-benzodiazepine hypnotic use for sleep disturbance in people aged over 55 years living with dementia: a series of cohort studies. Health Technology Assessment, 2021, 25, 1-202.	2.8	7
7	FDG-PET assessment of the locus coeruleus in Alzheimer's disease. NeuroImage Reports, 2021, 1, 100002.	1.0	9
8	The need to show minimum clinically important differences in Alzheimer's disease trials. Lancet Psychiatry,the, 2021, 8, 1013-1016.	7.4	60
9	Can we learn lessons from the FDA's approval of aducanumab?. Nature Reviews Neurology, 2021, 17, 715-722.	10.1	66
10	Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2021, 398, 1487-1497.	13.7	31
11	Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD. Journal of the American Medical Directors Association, 2020, 21, 194-200.	2.5	21
12	Questions EMERGE as Biogen claimsÂaducanumab turnaround. Nature Reviews Neurology, 2020, 16, 63-64.	10.1	98
13	Antipsychotic prescribing to people with dementia during COVID-19. Lancet Neurology, The, 2020, 19, 892.	10.2	56
14	Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet, The, 2020, 396, 413-446.	13.7	4,658
15	Functional cognitive disorder: dementia's blind spot. Brain, 2020, 143, 2895-2903.	7.6	84
16	The Relationship Between Anxiety and Incident Agitation in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 78, 1119-1127.	2.6	9
17	Sedative Load in Community-Dwelling Older Adults with Mild–Moderate Alzheimer's Disease: Longitudinal Relationships with Adverse Events, Delirium and Falls. Drugs and Aging, 2020, 37, 829-837.	2.7	5
18	Noradrenergic-dependent functions are associated with age-related locus coeruleus signal intensity differences. Nature Communications, 2020, 11, 1712.	12.8	74

#	Article	IF	CITATIONS
19	Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, th RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-62.	iree-arm 0.7	10
20	Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain, 2019, 142, 2558-2571.	7.6	219
21	Trazodone use and risk of dementia: A population-based cohort study. PLoS Medicine, 2019, 16, e1002728.	8.4	29
22	Blood Pressure Lowering With Nilvadipine in Patients With Mildâ€toâ€Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. Journal of the American Heart Association, 2019, 8, e011938.	3.7	10
23	The Incidence of Nonaffective, Nonorganic Psychotic Disorders in Older People: A Population-based Cohort Study of 3 Million People in Sweden. Schizophrenia Bulletin, 2019, 45, 1152-1160.	4.3	22
24	InÂvivo visualization of age-related differences in the locus coeruleus. Neurobiology of Aging, 2019, 74, 101-111.	3.1	117
25	Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very lateâ€onset schizophreniaâ€like psychosis (VLOSLP). International Journal of Geriatric Psychiatry, 2018, 33, 396-404.	2.7	18
26	The incidence of very late-onset psychotic disorders: a systematic review and meta-analysis, 1960–2016. Psychological Medicine, 2018, 48, 1775-1786.	4.5	58
27	Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Medicine, 2018, 15, e1002660.	8.4	131
28	Diagnosed depression and sociodemographic factors as predictors of mortality in patients with dementia. British Journal of Psychiatry, 2018, 213, 471-476.	2.8	15
29	Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial. Lancet Psychiatry,the, 2018, 5, 553-563.	7.4	53
30	Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT. Health Technology Assessment, 2018, 22, 1-62.	2.8	5
31	Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data. American Journal of Geriatric Psychiatry, 2017, 25, 708-716.	1.2	10
32	Efficacy of Antidepressants for Depression in Alzheimer's Disease: Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2017, 58, 725-733.	2.6	140
33	Dementia prevention, intervention, and care. Lancet, The, 2017, 390, 2673-2734.	13.7	4,228
34	Costâ€effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the) Tj ETQq0 0 0) rgBT <u>/</u> Over 2.7	rlock 10 Tf 50
35	Service and treatment engagement of people with very late-onset schizophrenia-like psychosis. BJPsych Bulletin, 2016, 40, 185-186.	1.1	17

³⁶The importance of high quality trials of cognitive interventions in Alzheimer's disease. International
Psychogeriatrics, 2016, 28, 705-706.1.02

#	Article	IF	CITATIONS
37	Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients. British Journal of Psychiatry, 2016, 209, 378-384.	2.8	13
38	European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease—the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow. BMJ Open, 2016, 6, e011584.	1.9	21
39	Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. International Psychogeriatrics, 2015, 27, 7-17.	1.0	244
40	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurology, The, 2015, 14, 1171-1181.	10.2	124
41	The Effect of an Online Cognitive Training Package in Healthy Older Adults: An Online Randomized Controlled Trial. Journal of the American Medical Directors Association, 2015, 16, 990-997.	2.5	143
42	Towards a therapeutic window of D2/3 occupancy for treatment of psychosis in Alzheimer's disease, with [¹⁸ F]fallypride positron emission tomography. International Journal of Geriatric Psychiatry, 2014, 29, 1001-1009.	2.7	13
43	Prescription of antipsychotics in people with dementia. British Journal of Psychiatry, 2014, 205, 4-5.	2.8	22
44	NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. BMJ Open, 2014, 4, e006364.	1.9	47
45	Does telecare prolong community living in dementia? A study protocol for a pragmatic, randomised controlled trial. Trials, 2013, 14, 349.	1.6	38
46	Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease. New England Journal of Medicine, 2012, 366, 893-903.	27.0	626
47	Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry, 2011, 26, 812-817.	2.7	126
48	The Cognitive and Affective Structure of Paranoid Delusions. Archives of General Psychiatry, 2009, 66, 236.	12.3	253
49	Brief Psychosocial Therapy for the Treatment of Agitation in Alzheimer Disease (The CALM-AD Trial). American Journal of Geriatric Psychiatry, 2009, 17, 726-733.	1.2	73
50	Non-pharmacological interventions in the prevention of delirium. Age and Ageing, 2009, 38, 374-379.	1.6	39
51	Cost-effectiveness of transcranial magnetic stimulation vs. electroconvulsive therapy for severe depression: A multi-centre randomised controlled trial. Journal of Affective Disorders, 2008, 109, 273-285.	4.1	40
52	A Randomized, Controlled Trial With 6-Month Follow-Up of Repetitive Transcranial Magnetic Stimulation and Electroconvulsive Therapy for Severe Depression. American Journal of Psychiatry, 2007, 164, 73-81.	7.2	157
53	Misunderstanding the Intentions of Others: An Exploratory Study of the Cognitive Etiology of Persecutory Delusions in Very Late-Onset Schizophrenia-Like Psychosis. American Journal of Geriatric Psychiatry, 2006, 14, 410-418.	1.2	55
54	Reasoning under uncertainty: heuristic judgments in patients with persecutory delusions or depression. Psychological Medicine, 2006, 36, 1109-1118.	4.5	49

#	Article	IF	CITATIONS
55	Neuroleptic drugs in dementia: benefits and harm. Nature Reviews Neuroscience, 2006, 7, 492-500.	10.2	257
56	Tract-specific anisotropy measurements in diffusion tensor imaging. Psychiatry Research - Neuroimaging, 2006, 146, 73-82.	1.8	148
57	Male gender influences response to an educational package for delirium prevention among older people: a stratified analysis. International Journal of Geriatric Psychiatry, 2006, 21, 493-497.	2.7	8
58	Prevention, diagnosis and treatment of delirium: staff educational approaches. Expert Review of Neurotherapeutics, 2006, 6, 741-751.	2.8	9
59	Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ: British Medical Journal, 2006, 332, 756-761.	2.3	424
60	An educational intervention can prevent delirium on acute medical wards. Age and Ageing, 2005, 34, 152-156.	1.6	167
61	The cerebellum and decision making under uncertainty. Cognitive Brain Research, 2004, 20, 46-53.	3.0	118
62	Spatial Normalization and Averaging of Diffusion Tensor MRI Data Sets. NeuroImage, 2002, 17, 592-617.	4.2	208
63	Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities. International Journal of Geriatric Psychiatry, 2002, 17, 140-145.	2.7	55
64	Isotropic resolution diffusion tensor imaging with whole brain acquisition in a clinically acceptable time. Human Brain Mapping, 2002, 15, 216-230.	3.6	172
65	PERSECUTORY DELUSIONS: A REVIEW AND THEORETICAL INTEGRATION. Clinical Psychology Review, 2001, 21, 1143-1192.	11.4	744
66	Guidelines for the management of agitation in dementia. International Journal of Geriatric Psychiatry, 2001, 16, 714-717.	2.7	101
67	Depression in older people with mild stroke, carotid stenosis and peripheral vascular disease: a comparison with healthy controls. International Journal of Geriatric Psychiatry, 2001, 16, 175-183.	2.7	42
68	Late-onset schizophrenia and very late-onset schizophrenia-like psychosis. Reviews in Clinical Gerontology, 2001, 11, 337-352.	0.5	7
69	TheFEAR: a rapid screening instrument for generalized anxiety in elderly primary care attenders. , 1999, 14, 60-68.		22
70	Neuropsychological Impairment in Stroke, Carotid Stenosis, and Peripheral Vascular Disease. Stroke, 1999, 30, 2167-2173.	2.0	69
71	The relationship between anxiety disorders and age. , 1998, 13, 79-99.		109
72	Cognitive impairment in late life schizophrenia: a suitable case for treatment?. , 1998, 13, 400-404.		1

Cognitive impairment in late life schizophrenia: a suitable case for treatment?. , 1998, 13, 400-404. 72

#	Article	IF	CITATIONS
73	Investigation of facial recognition memory and happy and sad facial expression perception: an fMRI study. Psychiatry Research - Neuroimaging, 1998, 83, 127-138.	1.8	191
74	Late paraphrenia revisited. British Journal of Psychiatry, 1997, 171, 406-408.	2.8	11
75	Seeing Visual Hallucinations with Functional Magnetic Resonance Imaging. Dementia and Geriatric Cognitive Disorders, 1997, 8, 73-77.	1.5	28
76	Drug Treatment of Schizophrenia and Delusional Disorder in Late Life. International Psychogeriatrics, 1996, 8, 597-608.	1.0	3
77	Statistical methods of estimation and inference for functional MR image analysis. Magnetic Resonance in Medicine, 1996, 35, 261-277.	3.0	644
78	Raymond Levy and paranoid states of late life. International Journal of Geriatric Psychiatry, 1996, 11, 355-361.	2.7	1
79	LETTER TO THE EDITOR. DEMOGRAPHIC AND PHENOMENOLOGICAL FEATURES OF A SPANISH POPULATION OF PATIENTS WITH LATE PARAPHRENIA. International Journal of Geriatric Psychiatry, 1996, 11, 745-747.	2.7	1
80	Schizophrenia and delusional disorder in late life. Reviews in Clinical Gerontology, 1996, 6, 63-73.	0.5	2
81	Apolipoprotein e genotype and late paraphrenia. International Journal of Geriatric Psychiatry, 1995, 10, 147-150.	2.7	22
82	White matter signal hyperintensities in the brains of patients with late paraphrenia and the normal, community-living elderly. Biological Psychiatry, 1995, 38, 86-91.	1.3	50
83	Phenomenology, demography and diagnosis in late paraphrenia. Psychological Medicine, 1994, 24, 397-410.	4.5	145
84	Demographic and clinical features of patients attending a memory clinic. International Journal of Geriatric Psychiatry, 1993, 8, 497-501.	2.7	30
85	A Comparative Study of 470 Cases of Early-Onset and Late-Onset Schizophrenia. British Journal of Psychiatry, 1993, 163, 352-357.	2.8	113
86	Differences in Late- and Early-Onset Schizophrenia. American Journal of Psychiatry, 1993, 150, 846-846.	7.2	6
87	Should the diagnosis of late paraphrenia be abandoned?. Psychological Medicine, 1992, 22, 11-14.	4.5	26
88	Do subjective memory complaints precede dementia? A threeâ€year followâ€up of patients with supposed †benign senescent forgetfulness'. International Journal of Geriatric Psychiatry, 1992, 7, 481-486.	2.7	79
89	Which factors affect treatment response in late paraphrenia?. International Journal of Geriatric Psychiatry, 1992, 7, 667-672.	2.7	40
90	Permeable walls, floors, ceilings and doors. Partition delusions in late paraphrenia. International Journal of Geriatric Psychiatry, 1992, 7, 719-724.	2.7	46